GlaxoSmithKline Stock Rating Reaffirmed by Bank of America Corp. (GSK)
GlaxoSmithKline (LON:GSK)‘s stock had its “buy” rating reaffirmed by Bank of America Corp. in a research note issued on Friday, Analyst Ratings News reports. They currently have a GBX 2,050 ($33.17) price target on the stock. Bank of America Corp.’s target price indicates a potential upside of 24.48% from the company’s current price.
A number of other analysts have also recently weighed in on GSK. Analysts at JPMorgan Chase & Co. cut their price target on shares of GlaxoSmithKline from GBX 1,900 ($30.74) to GBX 1,750 ($28.31) in a research note to investors on Wednesday. They now have a “neutral” rating on the stock. Separately, analysts at Barclays cut their price target on shares of GlaxoSmithKline from GBX 1,555 ($25.16) to GBX 1,545 ($25.00) in a research note to investors on Tuesday. They now have an “equal weight” rating on the stock. Finally, analysts at Societe Generale reiterated a “buy” rating on shares of GlaxoSmithKline in a research note to investors on Thursday, October 24th. They now have a GBX 2,000 ($32.36) price target on the stock. Five investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of GBX 1,622.52 ($26.25).
GlaxoSmithKline (LON:GSK) traded up 0.20% during mid-day trading on Friday, hitting GBX 1646.7899. The stock had a trading volume of 6,524,789 shares. GlaxoSmithKline has a 52-week low of GBX 556.50 and a 52-week high of GBX 2076.00. The stock has a 50-day moving average of GBX 1586. and a 200-day moving average of GBX 1654.. The company’s market cap is £79.326 billion.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.